Skip to content

A clinical study on compound Unani formulation in Dyslipidemia.

Clinical Evaluation of Dawa ul Luk in the management of Dyslipidemia (Dasumat e- dam): An Open Label Single Arm Study. - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105602
Enrollment
30
Registered
2026-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E780- Pure hypercholesterolemia

Interventions

Intervention1: Dawa ul luk: 7 gm at morning for 45 days. Control Intervention1: NIL: NIL

Sponsors

Ayurvedic and Unani Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Clinically diagnosed patients of dyslipidemia. 2.Primary inclusion window: Patients with mild to severe dyslipidemia (borderline to high) with Total Cholesterol level 200 mg per dl or more. 3.Patients who are willing and able to provide written informed consent. 4.Patients who are able to understand and follow the study protocol for the entire duration of the study.

Exclusion criteria

Exclusion criteria: 1.Presence of secondary dyslipidemia. 2. Patients with diabetes mellitus or any other endocrinal disorders, cardiovascular disease, uncontrolled hypertension, renal insufficiency, or any other chronic illness and patient with terminal medical conditions such as AIDS, cancer etc. 3.Pregnant and lactating women. 4. Patient taking any medication that might affect serum lipids. (thyroid or steroid hormones, beta blocker, prednisolone or diuretics etc). 5. Patient who refuse written consent form for the study. 6.Patients not willing to report for follow up. 7.Exclusion by patient history & investigations if needed.

Design outcomes

Primary

MeasureTime frame
1.To evaluate the efficacy and safety of the proposed compound unani formulation in the treatment of dyslipidemia by assessing changes in lipid profile parameters on scientific parameters.Timepoint: 1.To evaluate efficacy: Assessment of lipid profile on baseline and 45th day. 2.To evaluate safety: Haemogram, LFT, KFT at baseline and 45th day.

Secondary

MeasureTime frame
Improvement in quality of life.Timepoint: Assessment of quality of life index at baseline and after 45th day.

Countries

India

Contacts

Public ContactMs Sayma Naaz

Ayurvedic and Unani Tibbia College and Hospital

drkhannaseem.akhtarkhan@gmail.com9810815997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026